Top Authors for All Days ending 2016-12-01: GROWTH Trends @Leaders in Pharmaceutical Business Intelligence (LPBI) Group
December 1, 2016 by 2012pharmaceutical
Top Authors for All Days ending 2016-12-01: GROWTH Trends @Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Curator: Aviva Lev-Ari, PhD, RN
Date |Views to Date |# of articles |NIH Clicks |Nature Clicks
12/1/2016
1,107,643
4,972
3,398
2,279
Be proud to be part of this team !!!
Forthcoming SEVEN e-Books in 2016 AND Eight e-Books on Amazon.com
https://pharmaceuticalintelligence.com/2016/04/24/new-e-book-titles-forthcoming-on-amazon-com-in-2016-from-lpbi-groups-biomed-e-series-forthcoming-cover-pages/
WE ARE ON AMAZON.COM
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
GROWTH TRENDS: e-Readers, # of articles, NIH Clicks, Nature Clicks
2013, 2014, 2015, 2016
Scientific Journal Site Statistics
Date |Views to Date |# of articles |NIH Clicks |Nature Clicks
07/29/2013 217,356 1,138 1,389 705
12/01/2013 287,645 1,428 1,676 828
02/09/2014 325,039 1,665 1,793 892
03/05/2014 338,958 1,717 1,830 965
03/21/2014 347,667 1,750 1,838 974
03/31/2014 352,683 1,768 1,869 991
05/12/2014 373.696 1,878 1,944 1,035
06/18/2014 393,111 1,992 1,982 1,087
7/27/2014 418,570 2,098 2.050 1,124
9/2/2014 444,222 2,226 2,104 1,170
10/9/2014 471,117 2,337 2,147 1,216
11/4/2014 492,736 2,471 2,194 1,234
2/15/2015 572,027 2,727 2,358 1,345
3/10/2015 591,520 2,808 2,373 1,369
6/7/2015 661,215 3,007 2,562 1,535
7/27/2015 694,298 3,085 2,583 1,572
8/18/2015 709,609 3,173 2,613 1,573
02/18/2016 886,454 4,162 2,911 1,813
Date |Views to Date |# of articles |NIH Clicks |Nature Clicks
12/1/2016
1,107,643
4,972
3,398
2,279
Be proud to be part of this team !!!
Top Authors for all days ending 2016-12-01 (Summarized)
Author
Views
Aviva Lev-Ari, PhD, RN
295,929
larryhbern
203,736
tildabarliya
43,869
sjwilliamspa
35,934
Dror Nir
23,073
Dr. Sudipta Saha
19,509
ritusaxena
14,934
Demet Sag, Ph.D., CRA, GCP
12,025
aviralvatsa
7,942
zraviv06
7,176
zs22
3,738
anamikasarkar
3,182
danutdaagmailcom
2,283
pkandala
2,097
Gail S Thornton
2,035
Alan F. Kaul, PharmD., MS, MBA, FCCP
1,975
Aashir Awan, Phd
1,775
megbaker58
1,408
jdpmd
1,345
Irina Robu
879
Ed Kislauskis
546
howarddonohue
521
evelinacohn
344
David Orchard-Webb, PhD
341
apreconasia
332
stuartlpbi
252
jukkakarjalainen
226
gerag2015
90
kellyperlman
59
Rosalind Codrington, PhD
29
Debashree
22
Top Posts for all days ending 2016-12-03 (Summarized)
All Time
Views
Home page / Archives
402,487
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? – Dr. Larry Bernstein
14,861
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) Aviva Lev-Ari, et al
9,080
Recent comprehensive review on the role of ultrasound in breast cancer management Dr. Dror Nir
6,720
Paclitaxel vs Abraxane (albumin-bound paclitaxel) Tilda Barliya, PhD
5,695
Our TEAM
Aviva Lev-Ari, PhD, RN
5,539
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)
Tilda Barliya, PhD
5,051
Akt inhibition for cancer treatment, where do we stand today?
Ziv Raviv, PhD
3,843
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses – Zohi Sternberg, PhD
3,740
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care – Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN
3,418
Volume One: Perspectives on Nitric Oxide in Disease Mechanisms
Editors: Dr. Larry Bernstein, Aviral Vatsa, PhD and Stephen J Williams, PhD
3,389
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad – Demet Sag, PhD
3,181
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo – Stephen J Williams, PhD
3,149
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications – Aviva Lev-Ari, PhD, RN
3,082
Founder
Aviva Lev-Ari, PhD, RN
3,075
BioMed e-Series – Aviva Lev-Ari, PhD, RN
2,944
The mechanism of action of the drug ‘Acthar’ for Systemic Lupus Erythematosus (SLE) Aviva Lev-Ari, PhD, RN et al
2,728
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology – Tilda Barliya, PhD
2,728
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets – Dr. Larry Bernstein, Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN
2,715
VISION
Aviva Lev-Ari, PhD, RN
2,527
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community – Dr. Larry Bernstein, Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN
2,487
Funding, Deals & Partnerships – Aviva Lev-Ari, PhD, RN
2,436
Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I
Dr. Larry Bernstein
2,318
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules – Stephen J Williams, PhD
2,260
Bone regeneration and nanotechnology – – Tilda Barliya, PhD
2,252
“The Molecular pathology of Breast Cancer Progression” – – Tilda Barliya, PhD
2,233
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging – Dror Nir, PhD
2,150
About
Aviva Lev-Ari, PhD, RN
2,036
In focus: Circulating Tumor Cells – Ritu Saxena, PhD
2,034
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation – Dr. Larry Bernstein
2,016
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical)
Larry H Bernstein, MD, FCAP and Justin D Pearlman, MD, PhD , FACC
1,983
Journal PharmaceuticalIntelligence.com – Aviva Lev-Ari, PhD, RN
1,977
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) – Justin D Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
1,967
Problems of vegetarianism – Sudipta Saha, PhD
1,903
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment – Sudipta Saha, PhD
1,844
DNA Structure and Oligonucleotides – Larry H Bernstein, MD, FCAP
1,796
Targeting the Wnt Pathway [7.11] – Larry H Bernstein, MD, FCAP
1,759
Biosimilars: CMC Issues and Regulatory Requirements – Aviva Lev-Ari, PhD, RN
1,726
Interaction of enzymes and hormones – Sudipta Saha, PhD
1,716
Nitric Oxide and Platelet Aggregation – Dr. Venkat S. Karra, Ph.D.
1,713
CD47: Target Therapy for Cancer – Tilda Barliya, PhD
1,712
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes –
Aviva Lev-Ari, PhD, RN
1,711
Introduction to Tissue Engineering; Nanotechnology applications
Tilda Barliya, PhD
1,666
Non-small Cell Lung Cancer drugs – where does the Future lie? –
Ritu Saxena, PhD
1,658
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node – Tilda Barliya, PhD
1,583
A Primer on DNA and DNA Replication – Larry H. Bernstein, MD, FCAP
1,572
Lipid Metabolism – Larry H. Bernstein, MD, FCAP
1,568
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB
Aviva Lev-Ari, PhD, RN
1,532
The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research – Stephen J Williams, PhD
1,489
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers – Aviva Lev-Ari, PhD, RN
1,459
Like this: Like Loading...
Leave a Reply